Li Weidong, Chen Mao, Xu Lishuai, Lv Zhan, Chen Li, Li Yiling, He WenFen
Department of Cardiology, Sichuan University, West China Hospital No. 37 Guoxue Alley Chengdu 610041 Sichuan Province China
Department of Cardiology, Affiliated Hospital of North Sichuan Medical College Sichuan Province China.
RSC Adv. 2019 Jan 9;9(3):1222-1229. doi: 10.1039/c8ra08662a.
Coxsackievirus B3 (CVB3)-induced myocardial damage always leads to serious heart failure by inducing cardiac injury. NLRP3 inflammasome activation has been identified as a central player in the pathogenesis of CVB3-induced viral myocarditis. Therefore, restraining NLRP3 inflammasome activation has been supposed to significantly alleviate the severity of myocardial damage and improve cardiac function. Morroniside (MR), one of the main iridoid glycosides, has the ability to depress the production of reactive oxygen species (ROS) and restrain the expression of caspase-3 and -9. Of importance, ROS and caspase are essential for NLRP3 inflammasome activation in response to CVB3 infection. Therefore, in the present study, MR was selected as a model drug to alleviate CVB3-induced myocardial damage. The results of cardiac function index determination showed that abnormal indexes including mean arterial pressure, heart rate, and left ventricular systolic pressure of myocardial damage rats could be recovered by treating with MR. Such results can be further verified by histopathological evaluation, with the heart tissues of CVB3-infected rats displaying the most amount of H&E and TUNEL positive cells. The underlying mechanism by which MR improves the cardiac function was subsequently investigated. The detection of various gene levels indicated that NLRP3 inflammasome activation was inhibited by MR through down-regulating the expression of pro-inflammatory cytokines: interleukin (IL)-β and IL-18, the pivotal factors that lead to inflammatory responses. More importantly, the related genes, cardiac function indexes, and various myocardial damage markers of normal rats treated with MR did not exhibit any obvious changes compared with the control group, indicating a satisfactory biocompatibility of MR. In summary, MR holds a great potential in the alleviation of CVB3-induced myocardial damage with a negligible cytotoxicity to normal heart tissues.
柯萨奇病毒B3(CVB3)诱导的心肌损伤总是通过引发心脏损伤导致严重的心力衰竭。NLRP3炎性小体激活已被确定为CVB3诱导的病毒性心肌炎发病机制中的关键因素。因此,抑制NLRP3炎性小体激活被认为可显著减轻心肌损伤的严重程度并改善心脏功能。莫诺苷(MR)是主要的环烯醚萜苷之一,具有降低活性氧(ROS)生成以及抑制半胱天冬酶-3和-9表达的能力。重要的是,ROS和半胱天冬酶对于CVB3感染后NLRP3炎性小体的激活至关重要。因此,在本研究中,选择MR作为减轻CVB3诱导的心肌损伤的模型药物。心功能指标测定结果显示,通过MR治疗可使心肌损伤大鼠的平均动脉压、心率和左心室收缩压等异常指标恢复正常。组织病理学评估可进一步验证这些结果,CVB3感染大鼠的心脏组织显示出最多的苏木精-伊红(H&E)和TUNEL阳性细胞。随后研究了MR改善心脏功能的潜在机制。各种基因水平检测表明,MR通过下调促炎细胞因子白细胞介素(IL)-β和IL-18的表达来抑制NLRP3炎性小体激活,而这两种细胞因子是引发炎症反应的关键因素。更重要的是,与对照组相比,用MR处理的正常大鼠的相关基因、心功能指标和各种心肌损伤标志物均未表现出任何明显变化,表明MR具有良好的生物相容性。总之,MR在减轻CVB3诱导的心肌损伤方面具有巨大潜力,对正常心脏组织的细胞毒性可忽略不计。